IngleWood and Mesa Verde Co-Investment Partners
| Audax Ventures | HCMH Ventures* | OrbiMed |
| BioFrontier Partners* | IBM | Oxford Bioscience Ventures |
| BioVeda | IDEO | Pacific Growth |
| BioVentures Investors | Imperial Bank | Perseus-Soros |
| Burrill & Company | INVESCO | Prism Ventures |
| CDIB | J&J Development Corporation* | ProQuest* |
| CMEA | JF Shea & Co* | RBC |
| Cross Atlantic | Kingsbury Associates | RCT BioVentures* |
| Domain Associates* | Life Science Partners* | Rivervest |
| Dresdner Kleinwort | Lilly BioVentures | Sanderling* |
| Euclid SR Partners | Lombard Odier & Cie | Sofinov* |
| Forward Ventures | Merrill Lynch (KECALP) | SR One |
| Foundation Medical Partners | Mitsui & Co | Trian Equities |
| GeneChem | Morningside | Tullis Dickerson |
| GIMV | Moss Forest Ventures | Utah Ventures |
| Hambrecht & Quist | Novartis* | Vector Fund Management |
| HBM | Novo A/S | vSpring Capital |
|
*Denotes round IngleWood led Denotes multi-deal partners |
||
